Keyword: Ninlaro

J&J CAR-T partner Legend aims for U.S. IPO. The FDA's not sure how many drugs and APIs come from China. Harbour teams with Mount Sinai on coronavirus.

Just a day after BMS said Empliciti had failed a multiple myeloma trial that could have widened its market, Takeda revealed Ninlaro had done the same.

AZ and Daiichi reported "impressive" data for DS-8201. J&J and Legend's CAR-T showed promise in multiple myeloma. South Korea jailed Samsung execs.

Back in June, Takeda scrapped a Ninlaro trial in rare disease light-chain (AL) amyloidosis. Saturday, it shared the data behind the decision.

In a phase 3 trial of Ninlaro as a first-line maintenance treatment in multiple myeloma, patients experienced significant survival benefits.

Takeda's working to grow Ninlaro into a blockbuster, but the drug failed a phase 3 test in systemic light-chain AL amyloidosis, crimping hopes for a new indication.

Takeda pulls an FDA filing for Ninlaro and is ordered to pay $155 million in a Shire patent case; a cancer startup gets Chinese investors' attention.

Takeda withdrew an FDA filing for Ninlaro in post-transplant maintenance because it doesn't yet have survival data the agency wants.

The Takeda-Shire deal passes investors; Sun suffers from a long list of allegations; J&J and Legend update CAR-T data.

Three years after its initial approval, Takeda’s Ninlaro may finally be ready to jump into a new indication.